Reported about 4 hours ago
MapLight Therapeutics debuted on the Nasdaq with a valuation of $787 million, opening at $19 per share, marking a nearly 12% increase from its IPO price of $17. The Redwood City-based biotech firm, which focuses on treatments for central nervous system disorders, raised $250.8 million by selling 14.75 million shares. Backed by Novo Holdings, MapLight is also notable for being the first public company under a regulatory provision amid the ongoing U.S. government shutdown, as many firms continue to navigate a challenging IPO environment.
Source: YAHOO